Viscus Biologics

Executive Summary

Viscus Biologics is a US-based contract development and manufacturing organization (CDMO) specializing in extracellular matrix (ECM) biomaterials for regenerative medicine. Founded in 2012 and headquartered in San Diego, the company offers end-to-end product realization services from concept through high-volume production, leveraging proprietary xeno-derived decellularized ECM technologies. As an ISO 13485 certified firm operating under FDA quality regulations, Viscus serves a growing market of tissue engineering and regenerative medicine developers seeking scalable, regulatory-compliant manufacturing solutions. The company's expertise in ECM processing positions it as a niche player in the biologics CDMO space, with potential to capture demand as cell and gene therapies increasingly rely on biomaterial scaffolds. However, as a private company with limited public disclosures, its financial performance and pipeline visibility are constrained. The regenerative medicine CDMO market is projected to grow steadily, driven by advancements in tissue engineering and wound healing applications. Viscus's differentiation lies in its focus on decellularized ECM, a complex but high-value substrate that commands premium pricing. With no disclosed funding rounds or revenue figures, the company's near-term outlook hinges on securing strategic partnerships and expanding manufacturing capacity to meet rising client demand.

Upcoming Catalysts (preview)

• Q4 2026Major CDMO contract with a top regenerative medicine company40% success
• Q2 2027FDA clearance of a client's ECM-based product manufactured by Viscus30% success
• Q3 2026Capacity expansion announcement (new facility or production line)50% success